Baricitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Limitation of Use: Use of Baricitinib in combination with other JAK inhibitors, biologic DMARDs or with potent immunosuppressants such as Azathioprine and cyclosporine is not recommended.
The recommended dose of Baricitinib in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid) is 1 mg once daily
It is not known if Baricitinib will harm an unborn baby. Because of the potential for serious adverse reactions in nursing infants, advice an Baricitinib treated woman not to breastfeed.
It is not known if Baricitinib will harm an unborn baby. Because of the potential for serious adverse reactions in nursing infants, advice an Baricitinib treated woman not to breastfeed.
Serious Infections: Avoid use of Baricitinib in patients with active, serious infection, including localized infections. If a serious infection develops, interrupt Baricitinib therapy until the infection is controlled. Do not give Baricitinib to patients with active tuberculosis.
Thrombosis: Use with caution in patients who may be at increased risk.
Gastrointestinal Perforations: Use with caution in patients who may be at increased risk.
Laboratory Assessment: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids.
Vaccinations: Avoid use of Baricitinib with live vaccines
Moderate Renal Impairment: Reduce dose to 1 mg once daily.
In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
Immunosuppressant
Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.
